The H ealth Care Select Sector SPDR is comprised of all the Health Care stocks inside the S&P 500 Index. Its expense ratio is only 0.08% and XLV has $41.2B in AUM. The simple case for overweighting U.S. Health Care is that XLV currently features a unique combination of a low beta, moderate growth, and excellent momentum and sentiment. XLV also offers terrific growth-at-a-reasonable-price features, but only on a forward basis. A GARP analysis based on historical metrics highlights an interesting divide worth watching.
November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.
The Fed has begun to reduce interest rates in the U.S. This decision will incentivize the deployment of funding in the healthcare industry. The top holdings of XLV are profitable firms, with a median expected growth rate of 6.53% in their revenues. The U.S. legislation that mandates drugmakers to lower the selling price of their medicine in the country will only be applied to Medicaid beneficiaries, which has a limited effect.
Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Health Care Select Sector SPDR ETF (XLV) is a passively managed exchange traded fund launched on December 16, 1998.
Healthcare sector trades at a historic discount due to patent expirations, managed care uncertainty, and drug pricing proposals, but pessimism is overdone. Key catalysts include potential M&A activity and likely continued NIH funding, both of which could drive sector recovery and rerating. XLV stands out among healthcare ETFs for its liquidity, high concentration in undervalued leaders, low turnover, and minimal fees.
XLV lags SPY by double digits over the past year, but Buffett's UNH bet, hedge fund buys and AI optimism hint at a healthcare revival.
Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Health Care Select Sector SPDR ETF (XLV) is a passively managed exchange traded fund launched on December 16, 1998.
Healthcare led July job gains with 55,000 new positions, as most other U.S. sectors showed little to no growth. Tap ETFs like XLV and VHT.
Investing in healthcare has long been a cornerstone of defensive, long-term growth strategies. It is, after all, a massive and expanding segment of the global economy.
The life expectancy has increased in the U.S. and worldwide, contributing to healthcare companies retaining their patients for longer periods. Investors pay low fees to hold XLV, since the expense ratio of this financial instrument is only 0.08%. For this year, the top ten holdings of XLV expect a median revenue growth rate of 7.3% and a median EBITDA growth rate of 33.82%.
TSLW may face pressure as the "Big, Beautiful Bill" axed EV tax credits and slashed support for clean energy.
June's solid jobs report, with 39K new roles in healthcare, may boost the outlook for ETFs like XLV, IHF, VHT and stocks like HCA, WELL, OHI.